118 related articles for article (PubMed ID: 2545372)
21. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
22. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix.
Carmignani CP; Hampton R; Sugarbaker CE; Chang D; Sugarbaker PH
J Surg Oncol; 2004 Sep; 87(4):162-6. PubMed ID: 15334630
[TBL] [Abstract][Full Text] [Related]
23. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
[TBL] [Abstract][Full Text] [Related]
24. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
25. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
26. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract][Full Text] [Related]
27. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
29. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
30. [Place of carbohydrate antigens in the spectrum of protein tumor markers in patients with tumors at different sites].
Reznikov IuP; Ul'ianov VI; Variukhin AS; Vanin AI; Vorontsova LP
Vopr Onkol; 1988; 34(1):51-6. PubMed ID: 3422524
[TBL] [Abstract][Full Text] [Related]
31. [Considerations in rational use of tumor markers in breast carcinoma].
Crombach G
Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
[TBL] [Abstract][Full Text] [Related]
32. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
33. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
Einarsson R; Lindman H; Bergh J
Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
[TBL] [Abstract][Full Text] [Related]
34. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
35. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
36. [Tumor markers and their significance in gynecologic oncology].
Melchert F; Kreienberg R
Gynakologe; 1980 Jun; 13(2):74-88. PubMed ID: 6299910
[No Abstract] [Full Text] [Related]
37. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control.
Staab HJ; Ahlemann LM; Anderer FA; Zwirner M; Schindler AE
Cancer Detect Prev; 1985; 8(1-2):35-45. PubMed ID: 4064050
[TBL] [Abstract][Full Text] [Related]
38. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
39. [Sense and nonsense of tumor markers in practice].
Joss R; Cerny T
Schweiz Med Wochenschr; 1990 May; 120(19):693-703. PubMed ID: 1693445
[TBL] [Abstract][Full Text] [Related]
40. [Value of plasma ribonuclease as a marker for gynecologic tumors and breast tumors].
Kraus H; Deinert S
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):20-2. PubMed ID: 3956957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
